Due to health issues, this site is no longer maintained and will be shut down shortly.

SGIOY Shionogi & Co Unsp/Adrs

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan. This is an ADR of a company whose stock trades outside of the U.S. as the symbol JT:4507.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$11.14    Pink
As of 03/23/2023     OTCMarkets

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Japan
Country of incorporation:  Japan
IPO date:  11/30/2018
Outstanding shares:  1,229,544,660
Average volume:  185,356
Market cap:   $13,697,127,512
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy